Values as of: 2025-04-27
COMMON STOCK | Packaged Foods |
Last Closing
USD 0.4588Change
0.00 (0.00)%Market Cap
USD 0.05BVolume
N/AAnalyst Target
N/AVerdict
Verdict
Comvita Limited, together with its subsidiaries, engages in research, manufacturing, marketing, and distribution nature health products in Australia, New Zealand, Greater China, rest of Asia, North America, Europe, the Middle East, Africa, and internationally. The company offers Manuka honey, propolis, olive leaf extract, medihoney, bundles, bulk packs, and elixirs and lozenges, as well as oral care and kids health products. It also provides solutions for digestive health, skin health, heart and metabolic health, and immunity. In addition, the company engages in the apiary ownership and forest management. It offers its products through supermarkets, department stores, and health stores, as well as online. Comvita Limited was incorporated in 1974 and is based in Te Puke, New Zealand.
Company Website : https://www.comvita.co.nz
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| GPDNF | Danone S.A |
N/A |
USD 53.23B |
| DANOY | Danone PK |
N/A |
USD 47.13B |
| ASBFF | Associated British Foods plc |
N/A |
USD 18.25B |
| KRYAF | Kerry Group plc |
N/A |
USD 17.78B |
| WLMIY | Wilmar International Ltd |
N/A |
USD 15.29B |
| WLMIF | Wilmar International Limited |
N/A |
USD 15.22B |
| GRBMF | Grupo Bimbo S.A.B. De C.V. |
N/A |
USD 12.93B |
| BMBOY | Grupo Bimbo SAB de CV ADR |
N/A |
USD 12.71B |
| WHGLY | WH Group Ltd ADR |
N/A |
USD 12.03B |
| WHGRF | WH Group Limited |
N/A |
USD 12.03B |
| Market Performance vs. Industry/Classification (Packaged Foods) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -31.80% | 15% | F | 16% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -31.80% | 15% | F | 15% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -70.59% | 18% | F | 12% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -70.59% | 18% | F | 12% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -73.78% | 23% | F | 26% | F | ||
| Dividend Return | 9.81% | 33% | F | 21% | F | ||
| Total Return | -63.97% | 25% | F | 29% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -14.42% | 26% | F | 20% | F | ||
| Dividend Return | -13.05% | 27% | F | 20% | F | ||
| Total Return | 1.37% | 31% | F | 33% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 31.68% | 68% | D+ | 69% | C- | ||
| Risk Adjusted Return | -41.18% | 22% | F | 18% | F | ||
| Market Capitalization | 0.05B | 56% | F | 52% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
This stock has shown below median revenue growth in the previous 5 years compared to its sector
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
